Morningstar

Pulse Biosciences Announces FDA IDE Approval to Initiate its nsPFA Cardiac Surgery System Study for the Treatment of Atrial Fibrillation

Pulse Biosciences, Inc. (Nasdaq: PLSE)(the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, ...
Nasdaq

Pulse Biosciences Announces FDA 510(k) Clearance for the Treatment of Sebaceous Hyperplasia

HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company developing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, ...
Business Wire

Theraclion Announces Treatment of First Patients With New SONOVEIN® ‘SpeedPulse’ Feature Accelerating Treatment

MALAKOFF, France--(BUSINESS WIRE)--Regulatory News: THERACLION (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing a robotic platform for non-invasive high-intensity focused ...
Seeking Alpha

Pulse Biosciences, Inc. Announces Initiation of Research Collaboration for the Treatment of Benign and Malignant Thyroid Tumors with nPulse™ Technology

HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed ...
Medscape

Treatment With Prehospital Pulse-Dose Glucocorticoid Fails to Reduce Infarct Size in Patients With ST-Segment Elevation Myocardial Infarction

Prehospital pulse-dose glucocorticoid treatment in patients with ST-segment elevation myocardial infarction (STEMI) does not reduce the final infarct size at 3 months but may improve acute outcomes ...
Psychology Today

Mind Pulse Center

If you're struggling with treatment-resistant depression, anxiety, or OCD, you're not alone—and you haven't run out of options. At Mind Pulse Center, we understand the frustration of trying medication ...
Seeking Alpha

Pulse Biosciences Announces FDA IDE Approval to Initiate its nPulse Cardiac Catheter Ablation System Study for the Treatment of Atrial Fibrillation

HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) ...